Company news

Allogene Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

April 12, 2023

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

March 29, 2023

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

March 13, 2023

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

March 1, 2023

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy

February 28, 2023

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 27, 2023

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

February 20, 2023

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

January 31, 2023

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

January 24, 2023

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

January 23, 2023

Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

January 2, 2023

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

November 28, 2022

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

November 9, 2022

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

November 2, 2022

Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase

November 1, 2022

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

October 30, 2022

Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022

October 25, 2022

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

October 10, 2022

Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

October 5, 2022

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

September 22, 2022

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

August 8, 2022

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

July 11, 2022

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

June 7, 2022

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 18, 2022

Allogene Therapeutics Reports First Quarter 2022 Financial Results

May 3, 2022

Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

April 27, 2022

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

April 26, 2022

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

April 13, 2022

Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma

March 22, 2022

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

March 9, 2022

Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 22, 2022

Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology

January 10, 2022

Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials

January 9, 2022

Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation

December 14, 2021

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

December 12, 2021

Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

November 30, 2021

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

November 11, 2021

Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update

November 3, 2021

Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021

October 27, 2021

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial

October 6, 2021

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

August 31, 2021

Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

August 11, 2021

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

August 3, 2021

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

August 1, 2021

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

June 29, 2021

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer

June 20, 2021

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

June 3, 2021

Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021

May 11, 2021

Allogene Therapeutics Reports First Quarter 2021 Financial Results

May 4, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.